Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

201 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era.
Toss A, Isca C, Venturelli M, Nasso C, Ficarra G, Bellelli V, Armocida C, Barbieri E, Cortesi L, Moscetti L, Piacentini F, Omarini C, Andreotti A, Gambini A, Battista R, Dominici M, Tazzioli G. Toss A, et al. Among authors: ficarra g. ESMO Open. 2021 Apr;6(2):100055. doi: 10.1016/j.esmoop.2021.100055. Epub 2021 Feb 12. ESMO Open. 2021. PMID: 33582382 Free PMC article.
GD2 expression in breast cancer.
Orsi G, Barbolini M, Ficarra G, Tazzioli G, Manni P, Petrachi T, Mastrolia I, Orvieto E, Spano C, Prapa M, Kaleci S, D'Amico R, Guarneri V, Dieci MV, Cascinu S, Conte P, Piacentini F, Dominici M. Orsi G, et al. Among authors: ficarra g. Oncotarget. 2017 May 9;8(19):31592-31600. doi: 10.18632/oncotarget.16363. Oncotarget. 2017. PMID: 28415563 Free PMC article.
Magnetic resonance imaging and ultrasonography in predicting infiltrating residual disease after preoperative chemotherapy in stage II-III breast cancer.
Guarneri V, Pecchi A, Piacentini F, Barbieri E, Dieci MV, Ficarra G, Tazzioli G, Frassoldati A, Battista R, Canossi B, Mauri C, D'Amico R, Conte P, Torricelli P. Guarneri V, et al. Among authors: ficarra g. Ann Surg Oncol. 2011 Aug;18(8):2150-7. doi: 10.1245/s10434-011-1590-x. Epub 2011 Feb 8. Ann Surg Oncol. 2011. PMID: 21301969
Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials.
Dieci MV, Frassoldati A, Generali D, Bisagni G, Piacentini F, Cavanna L, Cagossi K, Puglisi F, Michelotti A, Berardi R, Banna G, Goubar A, Ficarra G, Griguolo G, Conte P, Guarneri V. Dieci MV, et al. Among authors: ficarra g. Breast Cancer Res Treat. 2017 Jun;163(2):295-302. doi: 10.1007/s10549-017-4191-y. Epub 2017 Mar 13. Breast Cancer Res Treat. 2017. PMID: 28289852
Immune characterization of breast cancer metastases: prognostic implications.
Dieci MV, Tsvetkova V, Orvieto E, Piacentini F, Ficarra G, Griguolo G, Miglietta F, Giarratano T, Omarini C, Bonaguro S, Cappellesso R, Aliberti C, Vernaci G, Giorgi CA, Faggioni G, Tasca G, Conte P, Guarneri V. Dieci MV, et al. Among authors: ficarra g. Breast Cancer Res. 2018 Jun 22;20(1):62. doi: 10.1186/s13058-018-1003-1. Breast Cancer Res. 2018. PMID: 29929548 Free PMC article.
Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials.
Dieci MV, Frassoldati A, Generali D, Bisagni G, Piacentini F, Cavanna L, Cagossi K, Puglisi F, Michelotti A, Berardi R, Banna G, Goubar A, Ficarra G, Griguolo G, Conte P, Guarneri V. Dieci MV, et al. Among authors: ficarra g. Breast Cancer Res Treat. 2017 Jun;163(3):637. doi: 10.1007/s10549-017-4219-3. Breast Cancer Res Treat. 2017. PMID: 28374322 No abstract available.
201 results